<DOC>
	<DOCNO>NCT00868660</DOCNO>
	<brief_summary>Healthy Normal Single Ascending Dose Crohn 's patient Multiple Ascending Dose</brief_summary>
	<brief_title>Healthy Normal Single Ascending Dose Crohn 's Patient Multiple Ascending Dose</brief_title>
	<detailed_description>A Phase I , Double blind , Placebo-controlled , safety tolerability study ZP1848 administer Ascending single Dose , SUBCUTANEOUS bolus injection healthy SUBJECTS follow Multiple Dose cohort patient stable Crohn 's disease remission</detailed_description>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<criteria>Healthy adult male and/or female , 18 50 year age Body mass index ( BMI ) 1830 . Chrons Inclusion Adult male and/or female , 18 60 year age ( inclusive ) . Body mass index ( BMI ) ≥ 18 ≤ 30 ( kg/m2 ) . Crohn 's Disease Activity Index ( CDAI ) score &lt; 150 . In stable state Crohn 's disease per Investigator 's opinion . Free steroid treatment ( therapy target GI tract ) within 3 month prior Day 1 . History presence dysplasia , cancer , chronic hepatitis , HIV , tuberculosis ( TB ) , histoplasmosis . Fistula within 3 month prior dose . 3 . Ostomy ( ostomy time past ) . 4 . Any surgery treatment inflammatory bowel disease ( IBD ) within 3 month prior Day 1 . 5 . Short Bowel Syndrome ( SBS ) . 6 . Any condition , chronic disease , prior therapy , opinion Investigator/Investigator 's designee would put patient undue risk would make patient unsuitable study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2010</verification_date>
</DOC>